AU4421697A
(en)
*
|
1996-09-19 |
1998-04-14 |
American Home Products Corporation |
Method of treating urinary incontinence
|
US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
IL141235A
(en)
*
|
2000-02-09 |
2012-04-30 |
Novartis Int Pharm Ltd |
Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
|
US7858119B1
(en)
*
|
2000-05-09 |
2010-12-28 |
Amina Odidi |
Extended release pharmaceuticals
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
DE10149674A1
(de)
*
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
US7163696B2
(en)
*
|
2001-10-11 |
2007-01-16 |
Pfizer Inc. |
Pharmaceutical formulations
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030185882A1
(en)
*
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
GB0129962D0
(en)
*
|
2001-12-14 |
2002-02-06 |
Pfizer Ltd |
Method of treatment
|
GB0207104D0
(en)
*
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
KR20070091049A
(ko)
|
2002-12-13 |
2007-09-06 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
US20040235857A1
(en)
*
|
2003-02-11 |
2004-11-25 |
Pfizer Inc |
Crystalline therapeutic agent
|
PA8597401A1
(es)
*
|
2003-03-14 |
2005-05-24 |
Pfizer |
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
|
US20040186046A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
NZ542097A
(en)
|
2003-04-29 |
2008-12-24 |
Pfizer Ltd |
5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
|
US7268147B2
(en)
*
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP2112920B1
(en)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20050043300A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Pfizer Inc. |
Piperazine derivatives
|
MXPA06002550A
(es)
*
|
2003-09-03 |
2006-06-20 |
Pfizer |
Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
|
RU2320369C2
(ru)
|
2003-09-12 |
2008-03-27 |
Пфайзер Инк. |
Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
|
US7309790B2
(en)
*
|
2003-10-03 |
2007-12-18 |
Pfizer Inc |
Chemical compounds
|
GB0327323D0
(en)
*
|
2003-11-24 |
2003-12-31 |
Pfizer Ltd |
Novel pharmaceuticals
|
US7572799B2
(en)
*
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
GB0402491D0
(en)
*
|
2004-02-04 |
2004-03-10 |
Pfizer Ltd |
Medicaments
|
US7629358B2
(en)
*
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US7687533B2
(en)
*
|
2004-03-18 |
2010-03-30 |
Pfizer Inc. |
N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
|
US20050215542A1
(en)
*
|
2004-03-23 |
2005-09-29 |
Pfizer Inc |
Compounds for the treatment of diseases
|
US7538141B2
(en)
*
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
AP2315A
(en)
*
|
2004-03-23 |
2011-11-04 |
Pfizer |
Formamide derivatives useful as adrenoceptor.
|
BRPI0509731A
(pt)
*
|
2004-04-07 |
2007-09-25 |
Pfizer |
pirazol[4,3-d]pirimidinas
|
WO2005123718A2
(en)
*
|
2004-06-15 |
2005-12-29 |
Pfizer Japan Inc. |
Benzimidazolone carboxylic acid derivatives
|
US7737163B2
(en)
*
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
EP1778686B9
(en)
|
2004-08-12 |
2009-07-08 |
Pfizer Limited |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
DK1786785T3
(da)
*
|
2004-08-26 |
2010-05-31 |
Pfizer |
Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
|
ES2355923T3
(es)
*
|
2004-08-26 |
2011-04-01 |
Pfizer, Inc. |
Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
|
MX2007005290A
(es)
*
|
2004-11-02 |
2007-07-09 |
Pfizer |
Derivados de sulfonilbencimidazol.
|
US20060111416A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
KR100927915B1
(ko)
|
2005-03-17 |
2009-11-19 |
화이자 인코포레이티드 |
통증 치료에 유용한 n-(n-설폰일아미노메틸)사이클로프로판카복사마이드 유도체
|
EP1866278A1
(en)
*
|
2005-03-28 |
2007-12-19 |
Pfizer, Inc. |
Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US20070149464A1
(en)
*
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
US7645786B2
(en)
*
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
MX2007015114A
(es)
*
|
2005-06-15 |
2008-02-15 |
Pfizer Ltd |
Arilpirazoles sustituidos.
|
US20080269233A1
(en)
*
|
2005-08-04 |
2008-10-30 |
Mark David Andrews |
Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
|
WO2007017752A1
(en)
*
|
2005-08-10 |
2007-02-15 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
CN101287462A
(zh)
|
2005-09-02 |
2008-10-15 |
塞拉维达公司 |
治疗疾病的疗法
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007109142A2
(en)
*
|
2006-03-17 |
2007-09-27 |
Oregon Health & Science University |
M3 muscarinic receptor antagonists for treating tumors
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
EP2258700A1
(en)
|
2006-05-09 |
2010-12-08 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US20100256357A1
(en)
*
|
2006-08-09 |
2010-10-07 |
Agouron Pharmaceuticals, Inc. |
Heterocycles useful as inhibitors of carbonic anhydrase
|
WO2008031221A1
(en)
*
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
MX2009000080A
(es)
*
|
2006-09-21 |
2009-01-23 |
Raqualia Pharma Inc |
Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
BRPI0808634A2
(pt)
*
|
2007-02-02 |
2014-08-05 |
Pfizer Prod Inc |
Compostos tricíclicos, composições e métodos.
|
JP2010527986A
(ja)
*
|
2007-05-24 |
2010-08-19 |
ファイザー・リミテッド |
スピロ環状キナゾリン誘導体およびpde7阻害剤としてのその使用
|
CN101084891A
(zh)
*
|
2007-06-29 |
2007-12-12 |
北京本草天源药物研究院 |
一种用于口服的达非那新或其药用盐的药物制剂
|
WO2009006413A1
(en)
*
|
2007-06-30 |
2009-01-08 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US8323695B2
(en)
|
2007-08-13 |
2012-12-04 |
Mcneil-Ppc, Inc. |
Method for stabilizing phenylephrine
|
CZ300895B6
(cs)
*
|
2008-01-28 |
2009-09-02 |
Zentiva, A. S. |
Zpusob prípravy Darifenacinu
|
WO2009105887A1
(en)
*
|
2008-02-26 |
2009-09-03 |
Ernest Puil |
Cyclic amino acids for the treatment of pain
|
WO2009140078A1
(en)
*
|
2008-05-16 |
2009-11-19 |
The Procter & Gamble Company |
Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
|
US20110217387A1
(en)
*
|
2008-05-16 |
2011-09-08 |
Axis, Inc. |
Pharmaceutical composition for treatment of fibromyalgia
|
JP5553452B2
(ja)
*
|
2008-05-30 |
2014-07-16 |
ユセベ ファルマ ソシエテ アノニム |
ブリバラセタムを含む医薬組成物
|
ES2378513T3
(es)
*
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
JP5621148B2
(ja)
|
2008-11-21 |
2014-11-05 |
ラクオリア創薬株式会社 |
5−ht2b受容体拮抗活性を有する新規ピラゾール−3−カルボキサミド誘導体
|
NZ593473A
(en)
|
2009-01-12 |
2013-02-22 |
Pfizer Ltd |
Sulfonamide derivatives
|
AU2010223268B2
(en)
|
2009-03-12 |
2015-04-23 |
Haase Investments Gmbh |
Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
EP2236516A1
(en)
|
2009-03-31 |
2010-10-06 |
Charité-Universitätsmedizin Berlin (Charité) |
Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
|
EP2435462A1
(en)
|
2009-05-29 |
2012-04-04 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8617763B2
(en)
*
|
2009-08-12 |
2013-12-31 |
Bloom Energy Corporation |
Internal reforming anode for solid oxide fuel cells
|
JP2013513615A
(ja)
|
2009-12-11 |
2013-04-22 |
イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー |
脂肪酸アミドヒドロラーゼのアゾ環状阻害薬
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
MX2012007402A
(es)
|
2009-12-23 |
2012-08-23 |
Takeda Pharmaceutical |
Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
|
GB2479213B
(en)
|
2010-04-01 |
2013-07-10 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
US8916593B2
(en)
|
2010-05-04 |
2014-12-23 |
Pfizer Inc. |
Alkoxy-substituted 2-aminopyridines as ALK inhibitors
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
WO2011161504A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Micro Labs Limited |
Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
|
WO2012004743A1
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
CA2804173C
(en)
|
2010-07-09 |
2015-01-13 |
Pfizer Limited |
Sulfonamide nav1.7 inhibitors
|
EP2590957B1
(en)
|
2010-07-09 |
2014-11-12 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
CA2800971A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
JP2013532186A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
CN103429595B
(zh)
|
2010-11-15 |
2015-10-21 |
Viiv保健英国有限公司 |
Hiv复制的抑制剂
|
EP2457900A1
(en)
|
2010-11-25 |
2012-05-30 |
Almirall, S.A. |
New pyrazole derivatives having CRTh2 antagonistic behaviour
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
CN102048706B
(zh)
*
|
2011-01-12 |
2012-02-22 |
山东创新药物研发有限公司 |
一种氢溴酸达非那新缓释片及制备方法
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
EP2489663A1
(en)
|
2011-02-16 |
2012-08-22 |
Almirall, S.A. |
Compounds as syk kinase inhibitors
|
CN103384672B
(zh)
|
2011-02-25 |
2016-09-28 |
武田药品工业株式会社 |
N-取代的噁嗪并喋啶和噁嗪并喋啶酮
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
AP2013007159A0
(en)
|
2011-04-05 |
2013-10-31 |
Pfizer Ltd |
Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
|
EP2518070A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as PI3K inhibitors
|
EP2518071A1
(en)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridine derivatives as PI3K inhibitors
|
AU2012253667B2
(en)
|
2011-05-10 |
2017-06-01 |
Theravida, Inc. |
Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
|
WO2012154775A1
(en)
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
|
JP5608873B2
(ja)
|
2011-05-18 |
2014-10-15 |
ラクオリア創薬株式会社 |
4−{[4−({[4−(2,2,2−トリフルオロエトキシ)−1,2−ベンズイソオキサゾール−3−イル]オキシ}メチル)ピペリジン−1−イル]メチル}−テトラヒドロ−2h−ピラン−4−カルボン酸の多形形態
|
EP2526945A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
New CRTH2 Antagonists
|
EP2527344A1
(en)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
|
JP6026525B2
(ja)
|
2011-06-22 |
2016-11-16 |
武田薬品工業株式会社 |
置換6−アザ−イソインドリン−1−オン誘導体
|
EP2548876A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists
|
EP2548863A1
(en)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
New CRTh2 antagonists.
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2554544A1
(en)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1h)-one derivatives as jak inhibitors
|
CA2842493A1
(en)
|
2011-08-02 |
2013-02-07 |
James Gail Christensen |
Crizotinib for use in the treatment of cancer
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
WO2013057624A1
(en)
|
2011-10-19 |
2013-04-25 |
Ah Usa 42 Llc |
Use of aminoacetonitrile derivatives against endoparasites
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
EA023375B1
(ru)
|
2011-10-26 |
2016-05-31 |
Пфайзер Лимитед |
Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
|
CA2853231C
(en)
|
2011-10-28 |
2020-08-04 |
Inhibitaxin Limited |
Pyridazine derivatives with autotaxin activity for use in therapy
|
US9085517B2
(en)
|
2011-12-15 |
2015-07-21 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
CN102579379B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种药物缓释制剂及其制备方法
|
CN102600096B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种达非那新缓释制剂及其制备方法
|
JP6067031B2
(ja)
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドPfizer Limited |
N−アミノスルホニルベンズアミド
|
CA2861439C
(en)
|
2012-02-03 |
2016-07-12 |
Pfizer Inc. |
Benzimidazole and imidazopyridine derivatives as sodium channel modulators
|
EA026155B9
(ru)
|
2012-03-06 |
2017-06-30 |
Пфайзер Инк. |
Макроциклические производные для лечения пролиферативных заболеваний
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
EP2833886B1
(en)
|
2012-04-04 |
2020-08-12 |
HangzhouDeRenYuCheng Biotechnology Ltd. |
Substituted quinolines as bruton's tyrosine kinase inhibitors
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
EP2900653A1
(en)
|
2012-09-28 |
2015-08-05 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
WO2014060431A1
(en)
|
2012-10-16 |
2014-04-24 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
RU2617842C2
(ru)
|
2012-11-08 |
2017-04-28 |
Пфайзер Инк. |
Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов
|
ES2652514T3
(es)
|
2012-11-08 |
2018-02-02 |
Pfizer Inc. |
Compuestos heteroaromáticos como ligandos de dopamina D1
|
JP5903681B2
(ja)
|
2012-11-21 |
2016-04-13 |
ラクオリア創薬株式会社 |
多形形態
|
MX368898B
(es)
|
2012-12-03 |
2019-10-21 |
Pfizer |
Moduladores selectivos del receptor de androgenos novedosos.
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
TW201446767A
(zh)
|
2013-02-15 |
2014-12-16 |
Almirall Sa |
作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
|
WO2014128588A1
(en)
|
2013-02-21 |
2014-08-28 |
Pfizer Inc. |
Solid forms of a selective cdk4/6 inhibitor
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
EP2968167A1
(en)
*
|
2013-03-13 |
2016-01-20 |
ratiopharm GmbH |
Dosage form comprising crizotinib
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
EP2997084A4
(en)
|
2013-05-17 |
2016-10-12 |
Acupac Packaging Inc |
ANHYDROUS HYDROGEL COMPOSITION
|
ES2729630T3
(es)
|
2013-06-27 |
2019-11-05 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015092614A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Inc. |
Activating notch alterations in breast cancer
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
UY35945A
(es)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
Derivados de azaindol
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
AU2015249496A1
(en)
|
2014-04-25 |
2016-09-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
CA2946475A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6564394B2
(ja)
|
2014-04-28 |
2019-08-21 |
ファイザー・インク |
複素環式化合物およびそのドーパミンd1リガンドとしての使用
|
EP3137454A1
(en)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
EA201650029A1
(ru)
|
2014-05-14 |
2017-09-29 |
Пфайзер Инк. |
Пиразолопиридины и пиразолопиримидины
|
PL3143019T3
(pl)
|
2014-05-15 |
2021-03-22 |
Pfizer Inc. |
Krystaliczna postać 6-[(4R)-4-metylo-1,2-dioksydo-1,2,6-tiadiazynan-2-ylo]izochinolino-1-karbonitrylu
|
WO2015178020A1
(en)
|
2014-05-20 |
2015-11-26 |
Raqualia Pharma Inc. |
Benzisoxazole derivative salt
|
JP2017516803A
(ja)
|
2014-05-30 |
2017-06-22 |
ファイザー・インク |
ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
BR112017015536B1
(pt)
|
2015-01-22 |
2021-05-18 |
Phytoplant Research S.L |
métodos de purificação de canabinoides
|
JP6584521B2
(ja)
|
2015-02-24 |
2019-10-02 |
ファイザー・インク |
抗がん剤として有用な置換ヌクレオシド誘導体
|
CA2979527A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
|
MA41938A
(fr)
|
2015-04-21 |
2018-02-28 |
Almirall Sa |
Dérivés hétérocycliques amino-substitués utilisés comme inhibiteurs des canaux sodiques
|
PT3302565T
(pt)
|
2015-06-04 |
2020-01-14 |
Pfizer |
Formas de dosagem sólida de palbociclib
|
JP6832914B2
(ja)
|
2015-07-31 |
2021-02-24 |
ファイザー・インク |
Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体
|
WO2017060488A1
(en)
|
2015-10-09 |
2017-04-13 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017064068A1
(en)
|
2015-10-14 |
2017-04-20 |
Almirall, S.A. |
New trpa1 antagonists
|
CA3007595C
(en)
|
2015-12-10 |
2020-08-25 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
PL3394045T3
(pl)
|
2015-12-24 |
2021-09-27 |
Takeda Pharmaceutical Company Limited |
Kokryształ, sposób jego wytwarzania i lek zawierający kokryształ
|
TWI726968B
(zh)
|
2016-01-07 |
2021-05-11 |
開曼群島商Cs醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
MX2018008653A
(es)
|
2016-01-15 |
2018-12-10 |
Pfizer |
Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
|
KR102495757B1
(ko)
|
2016-01-20 |
2023-02-06 |
테라비다, 인코포레이티드 |
다한증을 치료하기 위한 방법 및 조성물
|
JP7112957B2
(ja)
|
2016-03-09 |
2022-08-04 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
腫瘍細胞懸濁培養及び関連方法
|
US20190105407A1
(en)
|
2016-03-31 |
2019-04-11 |
Takeda Pharmaceutical Company Limited |
Isoquinolinyl triazolone complexes
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
CN109789144B
(zh)
|
2016-08-12 |
2022-04-15 |
马德拉医疗公司 |
蛋白激酶调节剂
|
BR112019002610A2
(pt)
|
2016-08-15 |
2019-07-02 |
Pfizer |
piridopirimidinonas inibidoras de cdk2/4/6
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
BR112019014099A2
(pt)
|
2017-01-23 |
2020-02-11 |
Pfizer Inc. |
Compostos espiro-heterocíclico como inibidores de magl
|
KR20190111086A
(ko)
|
2017-01-24 |
2019-10-01 |
화이자 인코포레이티드 |
칼리키아마이신 유도체 및 이의 항체 약물 접합체
|
EP3600312B1
(en)
|
2017-03-26 |
2023-05-17 |
Takeda Pharmaceutical Company Limited |
Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
WO2018234808A1
(en)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
MODULATORS WITH SMALL MOLECULES OF STING HUMAIN
|
MX2020002303A
(es)
|
2017-08-30 |
2020-09-10 |
Beijing Xuanyi Pharmasciences Co Ltd |
Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
|
MA50245A
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals Inc |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
EP3710057A1
(en)
|
2017-11-14 |
2020-09-23 |
Pfizer Inc |
Ezh2 inhibitor combination therapies
|
AU2019211188A1
(en)
|
2018-01-29 |
2020-07-30 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
EP3758753A1
(en)
|
2018-02-27 |
2021-01-06 |
Pfizer Inc |
Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
EP3784664A1
(en)
|
2018-04-26 |
2021-03-03 |
Pfizer Inc |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
WO2020016710A1
(en)
|
2018-07-19 |
2020-01-23 |
Pfizer Inc. |
Heterocyclic spiro compounds as magl inhibitors
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
TWI732431B
(zh)
|
2019-01-23 |
2021-07-01 |
美商輝瑞股份有限公司 |
多形體
|
BR112021012635A2
(pt)
|
2019-01-31 |
2021-12-14 |
Pfizer |
Compostos de 3-carbonilamino-5-ciclopentil-1 fi-pirazol tendo atividade inibitória sobre cdk2
|
US20220125777A1
(en)
|
2019-02-01 |
2022-04-28 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
AU2020228047A1
(en)
|
2019-02-27 |
2021-09-30 |
Madera Therapeutics, LLC |
Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
GB201905371D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
GB201905375D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
MA55804A
(fr)
|
2019-04-29 |
2022-04-06 |
Solent Therapeutics Llc |
Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
CN114269720A
(zh)
|
2019-07-25 |
2022-04-01 |
库拉德夫制药私人有限公司 |
乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
|
GB201912674D0
(en)
|
2019-09-04 |
2019-10-16 |
Mission Therapeutics Ltd |
Novel compounds
|
AU2020348675A1
(en)
|
2019-09-16 |
2022-04-14 |
Takeda Pharmaceutical Company Limited |
Azole-fused pyridazin-3(2H)-one derivatives
|
AU2021219370A1
(en)
|
2020-02-12 |
2022-08-25 |
Curadev Pharma Pvt. Ltd. |
Small molecule STING antagonists
|
WO2021176349A1
(en)
|
2020-03-05 |
2021-09-10 |
Pfizer Inc. |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
IL296998A
(en)
|
2020-04-08 |
2022-12-01 |
Mission Therapeutics Ltd |
N-cyanopyrrolidines with activity as usp30 inhibitors
|
CR20220548A
(es)
|
2020-05-01 |
2022-12-12 |
Pfizer |
Compuestos de azalactama como inhibidores de hpk1
|
CN115515933A
(zh)
|
2020-05-04 |
2022-12-23 |
武田药品工业株式会社 |
经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
CN115667252A
(zh)
|
2020-05-28 |
2023-01-31 |
特殊治疗有限公司 |
用于治疗线粒体功能障碍的作为usp30抑制剂的n-(1-氰基-吡咯烷-3-基)-5-(3-(三氟甲基)苯基)噁唑-2-甲酰胺衍生物和对应噁二唑衍生物
|
AU2021285130A1
(en)
|
2020-06-04 |
2023-01-19 |
Mission Therapeutics Limited |
N-cyanopyrrolidines with activity as USP30 inhibitors
|
US20230312580A1
(en)
|
2020-06-08 |
2023-10-05 |
Mission Therapeutics Limited |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018596A1
(en)
|
2020-07-20 |
2022-01-27 |
Pfizer Inc. |
Combination therapy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
KR20230057384A
(ko)
|
2020-08-13 |
2023-04-28 |
화이자 인코포레이티드 |
조합 요법
|
CA3195063A1
(en)
|
2020-09-15 |
2022-03-24 |
Pfizer Inc. |
Solid forms of a cdk4 inhibitor
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
GB202016800D0
(en)
|
2020-10-22 |
2020-12-09 |
Mission Therapeutics Ltd |
Novel compounds
|
WO2022137174A1
(en)
|
2020-12-22 |
2022-06-30 |
Pfizer Inc. |
Solid forms of an eif4e inhibitor
|
AU2021404974A1
(en)
|
2020-12-24 |
2023-07-06 |
Pfizer Inc. |
Solid forms of a cdk2 inhibitor
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
CA3214316A1
(en)
|
2021-03-24 |
2022-09-29 |
Pfizer Inc. |
Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
WO2022207673A1
(en)
|
2021-03-31 |
2022-10-06 |
Sevenless Therapeutics Limited |
Sos1 inhibitors and ras inhibitors for use in the treatment of pain
|
CA3214567A1
(en)
|
2021-04-07 |
2022-10-13 |
Martin AMBLER |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
WO2022229846A1
(en)
|
2021-04-29 |
2022-11-03 |
Pfizer Inc. |
Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
|
CR20230604A
(es)
|
2021-06-26 |
2024-02-19 |
Array Biopharma Inc |
Inhibidores de mutación de her2
|
WO2023002362A1
(en)
|
2021-07-22 |
2023-01-26 |
Pfizer Inc. |
Treatment of hematological malignancy
|
TW202321232A
(zh)
|
2021-08-11 |
2023-06-01 |
印度商裘拉德製藥私人有限公司 |
小分子sting拮抗劑
|
CN118019738A
(zh)
|
2021-08-11 |
2024-05-10 |
库拉德夫制药私人有限公司 |
作为sting拮抗剂的小分子脲衍生物
|
WO2023084459A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating sars-cov-2
|
KR20240110971A
(ko)
|
2021-12-01 |
2024-07-16 |
푼다시온 델 섹토르 푸블리코 에스타탈 센트로 나시오날 데 인베스티가시오네스 온콜로지카스 카를로스 3 (에프.에스.피 씨엔아이오) |
화합물
|
WO2023099561A1
(en)
|
2021-12-01 |
2023-06-08 |
Mission Therapeutics Limited |
Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
|
KR20240112932A
(ko)
|
2021-12-02 |
2024-07-19 |
화이자 인코포레이티드 |
암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
TW202410897A
(zh)
|
2022-07-15 |
2024-03-16 |
愛爾蘭商爵士製藥愛爾蘭公司 |
聯芳醚脲化合物
|
US20240109915A1
(en)
|
2022-07-29 |
2024-04-04 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024033513A1
(en)
|
2022-08-11 |
2024-02-15 |
Diaccurate |
Compounds for treating cancer
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
WO2024105363A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
|
US20240238250A1
(en)
|
2023-01-13 |
2024-07-18 |
Neurim Pharmaceuticals (1991) Ltd. |
Method of using piromelatine for treating parasomnias associated with loss of rem sleep atonia
|
WO2024157205A1
(en)
|
2023-01-26 |
2024-08-02 |
Takeda Pharmaceutical Company Limited |
1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
|